Source comparison
MOTS-c NAD+ for Mitochondrial Research: Comparison of Mitochondrial-Targeted Interventions
The following table compares MOTS-c to other NAD+-modulating compounds used in mitochondrial research, focusing on mechanism of action, dosing requirements, and measurable outcomes. MOTS-c AMPK activation → NAMPT upregulation 5–15 mg/kg, 3×/week 72–96 hours fo
This comparison does not assign a generated winner or score.
- The following table compares MOTS-c to other NAD+-modulating compounds used in mitochondrial research, focusing on mechanism of action, dosing requirements, and measurable outcomes.
- MOTS-c
- AMPK activation → NAMPT upregulation
- 5–15 mg/kg, 3×/week
- 72–96 hours for 30–40% increase
- Insulin sensitivity, mitochondrial biogenesis, glucose tolerance
- Best-in-class for insulin resistance models; requires consistent dosing to maintain NAD+ elevation; effects are highly context-dependent on baseline metabolic state
- NMN (Nicotinamide Mononucleotide)
- Direct NAD+ precursor substrate
- 300–500 mg/kg daily oral
- 60–90 minutes for acute spike, sustained with daily dosing
- Modest improvements in endurance, vascular function
- Effective for acute NAD+ replenishment but does not address upstream metabolic signaling; limited insulin sensitivity effects
- NR (Nicotinamide Riboside)
- NAD+ precursor via NRK pathway
- 400–1000 mg/kg daily oral
- 90–120 minutes for acute elevation
- Neuroprotection, mitochondrial biogenesis in liver
- Similar to NMN but with better oral bioavailability; does not activate AMPK
- Metformin
- AMPK activation via complex I inhibition
- 200–300 mg/kg daily oral
- Indirect. No direct NAD+ elevation
- Insulin sensitivity, reduced hepatic glucose output
- Gold-standard for metabolic research but lacks mitochondrial biogenesis effects; MOTS-c produces comparable insulin effects without gastrointestinal side effects
- Resveratrol
- SIRT1 activation (NAD+-dependent deacetylase)
- 20–50 mg/kg daily oral
- Indirect via increased NAD+ utilization
- Mitochondrial biogenesis, lifespan extension in some models
- Requires supraphysiological doses; oral bioavailability is poor; MOTS-c produces more consistent metabolic outcomes
- MOTS-c stands apart from NAD+ precursors because it addresses the upstream regulatory machinery. The cell's ability to produce NAD+ on demand. Rather than simply flooding the system with substrate. For researchers studying metabolic resilience or age-related NAD+ decline, MOTS-c offers a more physiologically relevant intervention than supplementation alone. However, the peptide's effects are tightly coupled to baseline metabolic state, meaning experimental design must account for diet, exercise status, and age of the research model.